Visual impairment and blindness due to macular diseases globally: A systematic review and meta-analysis

American Journal of Ophthalmology

Volumn 158, Issue 4, 2014, Pages 808-815

  Jonas, Jost B ^a,l   Bourne, Rupert R A ^b   White, Richard A ^c   Flaxman, Seth R ^d   Keeffe, Jill ^e   Leasher, Janet ^f   Naidoo, Kovin ^g   Pesudovs, Konrad ^h   Price, Holly ^b   Wong, Tien Y ⁱ   Resnikoff, Serge ^j   Taylor, Hugh R ^k  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d Carnegie Mellon University   (United States)

^e L V PRASAD EYE INSTITUTE   (India)

^f NOVA SOUTHEASTERN UNIVERSITY   (United States)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h FLINDERS UNIVERSITY   (Australia)

ⁱ SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^j BRIEN HOLDEN VISION INSTITUTE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGE RELATED MACULAR DEGENERATION; BLINDNESS; DIABETIC RETINOPATHY; HUMAN; INCOME; POPULATION; PREVALENCE; PRIORITY JOURNAL; RETINA MACULOPATHY; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT; HEALTH; LOW VISION; META ANALYSIS; PATIENT; RETINA DISEASE; RETINA MACULA LUTEA; STATISTICS;

BLINDNESS; HUMANS; MACULA LUTEA; PREVALENCE; RETINAL DISEASES; VISION, LOW; VISUAL ACUITY; VISUALLY IMPAIRED PERSONS; WORLD HEALTH;

EID: 84908510528     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.06.012     Document Type: Article

References (18)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-1444.
3. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-1908.
4. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-943.
5. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of agerelated maculopathy in Australia: The Blue Mountains Eye Study. Ophthalmology 1995;102(10):1450-1460.
6. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci 2001;42(10): 2237-2241.
7. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-126.
8. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology 2010;117(5):921-927.
9. Wong WL, Su X, Li X, et al. Global prevalence and burden of age-related macular degeneration: A meta-analysis and disease burden projection for 2020 and 2040. Lancet Global Health 2014;2:e106-e116.
10. Stevens G, White R, Flaxman SR, et al. Global prevalence of visual impairment and blindness: magnitude and temporal trends, 1990-2010. Ophthalmology 2013;120(12):2377-2384.
11. Bourne R, Stevens GA, White RA, et al. Causes of global visual loss: 1990-2010. The Global Burden of Disease Study. Lancet Global Health 2013; http://dx.doi.org/10.1016/S2214-109X(13)70113-X.
12. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-2223.
13. Ahmad O B, Boschi-Pinto C, Lopez AD, Murray CJL, LozanoR, Inoue M. Age standardization of rates: A new WHO standard. GPE Discussion Paper Series No. 31. EIP/GPE/EBD. Geneva, Switzerland: World Health Organization, 2001.
14. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: The Baltimore Eye Survey. Ophthalmology 1999;106(6):1049-1055.
15. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: A meta-analysis. Ophthalmology 2012;119(3):571-580.
16. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in an urban and rural area in Beijing: The Beijing Eye Study. Ophthalmology 2006;113(7):11-41. e1-3.
17. Iwase A, Araie M, Tomidokoro A, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: The Tajimi Study. Ophthalmology 2006;113(8):1354-1362.
18. Wu L, Sun X, Zhou X, Weng C. Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001-2009. BMC Ophthalmol 2011;11:10.